# STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1

> **NCT07038915** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Lung Squamous Cell Carcinoma
- Anti-PD1/PDL1 Antibody

## Interventions

- **DRUG:** Tiragolumab
- **DRUG:** Ivonescimab

## Key facts

- **NCT ID:** NCT07038915
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-07-28
- **Primary completion:** 2025-07-28
- **Final completion:** 2025-07-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0 participants
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07038915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07038915, "STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07038915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*